Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001766:Blindness / Q000188:drug therapy; D001792:Blood Platelets / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D008297:Male; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D005343:Fibrinolytic Agents; D011743:Pyrimidines; D014859:Warfarin; D004176:Dipyridamole; D002994:Clofibrate; D001241:Aspirin; D013442:Sulfinpyrazone